Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2019-05-29 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Morepen Laboratories Ltd has informed BSE regarding Issuance of Duplicate Share Certificates of the Company
Share Issue/Capital Change Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes details of share certificate replacements for shareholders. There is no financial data, earnings information, management discussion, or report publication mentioned. The content is about a corporate action related to share certificates, which falls under announcements related to share capital changes or share certificates. This is not a full report or financial statement but an announcement of a corporate action regarding shares. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length is sufficient and the content is detailed about the share certificates issued as duplicates, not just a brief notice or regulatory filing. Confidence is high due to clear subject and content match.
2019-05-29 English
Morepen Laboratories Ltd has informed BSE regarding Loss of Share Certificates of the Company
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (NSE and BSE) informing them about the loss of share certificates by shareholders and the request for issuance of duplicate share certificates. It references Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to reporting loss of share certificates. The content is a notification about share certificate loss and does not contain financial data, earnings, management changes, or other report types. It is not a report itself but an official regulatory notification to the stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-05-24 English
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period ....
Regulatory Filings Classification · 95% confidence The document is titled 'Annual Secretarial Compliance Report for the year ended 31st March, 2019' and is issued by a practicing company secretary. It certifies compliance with various SEBI regulations and stock exchange requirements for the fiscal year ending 31 March 2019. The document includes examination of filings, records, and compliance with SEBI acts and regulations. It is a compliance certification report rather than a financial report or announcement. It does not contain financial statements or management discussion but focuses on regulatory compliance. This type of document fits best under Regulatory Filings (RNS) as it is a compliance report submitted to stock exchanges and regulatory bodies, not an annual report or audit report. The document length is about 5968 characters, which is sufficient for a full compliance report rather than a brief announcement.
2019-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an investor and analyst conference call discussing the quarterly financial results for Q4 FY 2018-19 of Morepen Laboratories Limited. It includes detailed management commentary on financial performance, business segments, growth, and outlook, followed by a Q&A session with analysts. The presence of a moderator, analyst questions, and management responses confirms it is a full call transcript. The document length is substantial (15,000 characters), and it contains the full text of the call, not just an announcement or summary. Therefore, the appropriate classification is Call Transcript (CT).
2019-05-22 English
Please find attached transcript of Investor and Analyst Conference Call organised on Wednesday, 8th May, 2019 at 4.00 P.M.(IST) subsequent to declaration of Audited Financial Results for ....
Call Transcript Classification · 100% confidence The document is a transcript of an investor and analyst conference call discussing the Q4 FY2018-19 financial results of Morepen Laboratories Limited. It includes detailed management commentary on financial performance, segment-wise growth, debt status, and future outlook, followed by a Q&A session. The presence of a moderator, analysts, and management representatives, along with the detailed discussion of quarterly results, clearly identifies this as a Call Transcript (CT). The document length (15,000 characters) and content confirm it is the full transcript, not just an announcement or summary.
2019-05-22 English
Related Party Transactions
Regulatory Filings Classification · 85% confidence The document contains detailed tables listing related parties, their relationships, and transactions such as sales, remuneration, and salaries. This type of disclosure is typical of notes to financial statements or related party transaction disclosures commonly found within annual or interim financial reports. However, the document length is only 1710 characters, which is quite short and does not contain comprehensive financial statements or analysis. It appears to be an excerpt or a note rather than a full report. There is no indication that this is an announcement or a certification. Given the content and length, it is most consistent with a Regulatory Filing (RNS) as a miscellaneous filing containing related party transaction disclosures without the full financial report context.
2019-05-21 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.